Amgen Inc. (AMGN)
| Market Cap | 206.95B +38.5% |
| Revenue (ttm) | 36.75B +10.0% |
| Net Income | 7.71B +88.5% |
| EPS | 14.23 +88.2% |
| Shares Out | 538.48M |
| PE Ratio | 27.01 |
| Forward PE | 17.17 |
| Dividend | $10.08 (2.62%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 3,840,234 |
| Open | 369.99 |
| Previous Close | 367.80 |
| Day's Range | 368.90 - 385.12 |
| 52-Week Range | 261.43 - 385.12 |
| Beta | 0.47 |
| Analysts | Hold |
| Price Target | 338.50 (-11.92%) |
| Earnings Date | Feb 3, 2026 |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for AMGN stock is "Hold." The 12-month stock price target is $338.5, which is a decrease of -11.92% from the latest price.
News
CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists
CVS Health said on Thursday it would swap out Amgen and Eli Lilly's bone disease treatments for lower-cost alternatives in some of its preferred drug lists, starting April 1.
Why Amgen Stock Is Paying Off Big For Long-Term Investors
Amgen's (AMGN) decade-long commitment to shareholder value is underscored by a staggering $86 billion capital return program, a feat that firmly establishes the biotech giant as a premier player in th...
Amgen: Strong Mitigation Of LOE Impact, Regulatory Tensions On Tavneos Emerge
Amgen delivered a strong Q4 2025, exceeding revenue and EPS expectations and guiding for 2026 growth despite major loss of exclusivity headwinds. Key branded products Repatha, Uplizna, Evenity, Imdell...
Amgen Inc. (AMGN) Q4 2025 Earnings Call Transcript
Amgen Inc. (AMGN) Q4 2025 Earnings Call Transcript
Amgen Logs Higher Fourth-Quarter Revenue on Double-Digit Volume Boost
The biotechnology company reported a quarterly profit of $1.33 billion, attributing its boost in earnings to higher revenue and lower net unrealized losses on equity investments.
Amgen quarterly results beat Street estimates on higher sales, lower tax rate
Amgen on Tuesday reported fourth-quarter financial results that came in ahead of Wall Street expectations, driven by a 7% increase in drug sales and a lower tax rate.
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
THOUSAND OAKS, Calif., Feb. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year of 2025 versus the comparable periods in 2024.
Obesity stocks slump on Novo's underwhelming 2026 sales forecast
Shares of obesity drugmakers and developers slid on Tuesday after Novo Nordisk forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the blockbuster weight-...
Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends
Kyowa Kirin Co., Ltd. and Amgen Inc. (NASDAQ: AMGN) terminated on Friday the current rocatinlimab development and commercialization collaboration.
AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
THOUSAND OAKS, Calif., Jan. 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 3, 2026, after...
Amgen: A Buy In 2026 On Exciting MariTide Obesity - T2D Potential
Amgen Inc. is rated a Buy, driven by robust pipeline prospects and the transformative potential of its obesity drug candidate MariTide. Recent AMGN performance includes 12% revenue growth in Q3 2025, ...
Nonprofit Health Services Organization Files Lawsuit Against Fortune 500 Pharmaceutical Company Over Prescription Drug Access
LAS VEGAS--(BUSINESS WIRE)--Sagebrush Health Services, a nonprofit organization serving over 10,000 Nevada patients, has filed a lawsuit against Amgen Inc. (NASDAQ: AMGN), alleging that Amgen acted un...
Amgen's Weight-Loss Drug Shows Promise With Less Frequent Dosing
Amgen reported early Phase 2 data suggesting patients kept weight off with less frequent dosing, a potential differentiator from Eli Lilly and Novo Nordisk.
Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses
At a J.P. Morgan Healthcare Conference on Monday, Amgen Inc. (NASDAQ: AMGN) CEO Robert Bradway shared findings from part 2 of the Phase 2 Study of MariTide, its investigational obesity treatment.
Amgen CEO Bob Bradway goes one-on-one with Jim Cramer
Amgen CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk its rare disease business, its weight-loss drug offering, what is in Amgen's pipeline, and more.
Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss
Amgen CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk its rare disease business, its weight-loss drug offering, what is in Amgen's pipeline, and more.
Amgen CEO says weight loss drug can address 'patient persistence issue'
Amgen CEO Bob Bradway told CNBC's Jim Cramer he thinks his company's obesity drug can help patients maintain weight loss, which he indicated is a challenge. "We think we can address one of the reasons...
Ro partners with Amgen to study barriers to obesity care, GLP-1 access
U.S. telehealth firm Ro said on Tuesday it has entered a research collaboration with drugmaker Amgen to examine challenges patients and providers face in accessing obesity treatments, including GLP-1 ...
Amgen Inc. (AMGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Amgen Inc. (AMGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Amgen says MariTide helped trial patients maintain weight loss
An extension study of Amgen's experimental obesity drug MariTide found that it helped people maintain weight loss while a second mid-stage trial in diabetes patients showed that it lowered their blood...
Amgen to announce data on obesity drug MariTide at healthcare conference
Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on Monday to unveil results from a mid-stage trial extension designed to show if ...
January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its single share price. Analyst projections suggest the top ten Dow Dogs could delive...
AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., Jan. 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2026 J.P.